Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H (HK:9989) has released an update.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. reports a significant increase in net profit for the first half of 2024, with earnings estimated to grow between 420.70% and 495.72% compared to the same period last year. The company attributes this performance to improved market demand in the heparin industry, successful brand expansion internationally, and enhanced cost efficiencies leading to greater gross profit margins for its main product, despite the impact of centralized procurement prices in China.
For further insights into HK:9989 stock, check out TipRanks’ Stock Analysis page.